Sep 10 |
Cardiol Therapeutics Announces Completion of the MAvERIC Phase II Study in Recurrent Pericarditis with Results to be Presented at the American Heart Association Scientific Sessions 2024
|
Jul 12 |
We're Keeping An Eye On Cardiol Therapeutics' (TSE:CRDL) Cash Burn Rate
|
Jun 27 |
Cardiol Therapeutics Reports Results of 2024 Annual General and Special Meeting of Shareholders
|
Jun 25 |
Cardiol Therapeutics to Webcast Virtual Annual General and Special Meeting of Shareholders on June 26th at 4:30 p.m. EDT
|
Jun 17 |
Hope on the Horizon: Results from MAvERIC-Pilot Show Heartfelt Progress for Patients
|
Jun 13 |
Cardiol Therapeutics Announces Positive Topline Data from its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis
|